

# CLINICAL TRIAL

**CIL 34546-NSR-REP-01**  
**NCT01461213**

Retinal RED



**Gene therapy study on choroideremia : to assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in patients with a diagnosis of choroideremia.**

Rare Eye Disease concerned by the trial :  
Choroideremia

Status of the trial : recruiting  
Orphan drug recognition : Yes

Inclusion criteria : Visual Acuity between 20/200 and 20/40

Exclusion criteria : age < 18 years



Inclusion  
opening date : 01/06/2017



Inclusion closing  
date (previsional) : 31/08/2018

Children



Adults



## Within ERN-EYE members



Principal location of the trial :

**Maolya - National Rare Disease center**  
Centre national de référence affections  
sensorielles génétiques  
CHU Gui de Chauliac  
80, avenue Augustin Fliche  
34 295 Montpellier Cedex 5

[Contact details](#)



Principal investigator name :


Isabelle Meunier



Other investigators :

**Moorfields Eye Hospital NHS Foundation Trust**  
London, United Kingdom, EC1V 2PD

**St Mary's Hospital**, Central Manchester University  
Hospitals NHS Foundation Trust  
Manchester, United Kingdom, M13 9WL



Funder type : Drug company - Industry

[More informations](#)